Six- and twelve-month results from first human experience using everolimus-eluting stents with bioabsorbable polymer

被引:140
作者
Grube, E
Sonoda, S
Ikeno, F
Honda, Y
Kar, S
Chan, C
Gerckens, U
Lansky, AJ
Fitzgerald, PJ
机构
[1] Stanford Univ, Med Ctr, Ctr Res Cardiovasc Intervent, Stanford, CA 94305 USA
[2] Heart Ctr Siegburg, Siegburg, Germany
[3] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[4] Natl Heart Ctr, Singapore, Singapore
[5] Cardiovasc Res Fdn, New York, NY USA
关键词
stents; restenosis; drugs; angioplasty; ultrasonics;
D O I
10.1161/01.CIR.0000128850.84227.FD
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background-Everolimus, an active immunosuppressive and antiproliferative agent of the same family as sirolimus (rapamycin), has demonstrated significant reduction of neointimal proliferation in animal studies. The First Use To Underscore restenosis Reduction with Everolimus (FUTURE) I trial was the first in-human experience to evaluate the safety and efficacy of everolimus-eluting stents (EES), coated with a bioabsorbable polymer, compared with bare metal stents (BMS). Methods and Results-FUTURE I was a prospective, single-blind, randomized trial that enrolled 42 patients with de novo coronary lesions (EES 27, BMS 15). Patient and lesion characteristics were comparable between the groups. Major adverse cardiac event rates were low at 30 days and 6 months, without any early or late stent thrombosis for either group (P = NS). Between 6 and 12 months, there were no additional reports of major adverse cardiac events. The 6-month angiographic in-stent restenosis rate was 0% versus 9.1% (1 patient) (P = NS), with an associated late loss of 0.11 mm versus 0.85 mm (P<0.001), and the in-segment restenosis rate was 4% (1 patient) and 9.1% (1 patient) (P = NS) for EES and BMS, respectively. Intravascular ultrasound analysis revealed a significant reduction of percent neointimal volume in EES compared with BMS (2.9 +/- 1.9 mm(3)/mm versus 22.4 +/- 9.4 mm(3)/mm, P<0.001). There was no late stent malapposition in either group. The safety and efficacy of the EES appeared to be sustained at 12 months. Conclusions-In this initial clinical experience, EES with bioabsorbable polymer demonstrated a safe and efficacious method to reduce in-stent neointimal hyperplasia and restenosis.
引用
收藏
页码:2168 / 2171
页数:4
相关论文
共 5 条
[1]  
CHAN C, IN PRESS CATHETER CA
[2]   Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model [J].
Cole, OJ ;
Shehata, M ;
Rigg, KM .
TRANSPLANTATION PROCEEDINGS, 1998, 30 (05) :2200-2203
[3]   Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients [J].
Eisen, HJ ;
Tuzcu, EM ;
Dorent, R ;
Kobashigawa, J ;
Mancini, D ;
Valantine-von Kaeppler, HA ;
Starling, RC ;
Sorensen, K ;
Hummel, M ;
Lind, JM ;
Abeywickrama, KH ;
Bernhardt, P .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (09) :847-858
[4]   SDZ RAD, a new rapamycin derivative - Pharmacological properties in vitro and in vivo [J].
Schuler, W ;
Sedrani, R ;
Cottens, S ;
Haberlin, B ;
Schulz, M ;
Schuurman, HJ ;
Zenke, G ;
Zerwes, HG ;
Schreier, MH .
TRANSPLANTATION, 1997, 64 (01) :36-42
[5]   SDZ RAD, a new rapamycin derivative - Synergism with cyclosporine [J].
Schuurman, HJ ;
Cottens, S ;
Fuchs, S ;
Joergensen, J ;
Meerloo, T ;
Sedrani, R ;
Tanner, M ;
Zenke, G ;
Schuler, W .
TRANSPLANTATION, 1997, 64 (01) :32-35